---
title: "Immunic names CEO Erik Lundgren to board after Tamar Howson retirement resignation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291840871.md"
description: "Immunic Inc. announced that director Tamar Howson resigned from the board and its compensation committee effective June 29, 2026, due to retirement. Consequently, CEO Erik Lundgren was appointed as a Class II director on July 5, 2026, with his term lasting until the 2028 annual meeting. Lundgren will not serve on any board committees."
datetime: "2026-07-06T20:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291840871.md)
  - [en](https://longbridge.com/en/news/291840871.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291840871.md)
generator: "portal-rs"
---

# Immunic names CEO Erik Lundgren to board after Tamar Howson retirement resignation

-   Immunic director Tamar Howson resigned from the board and its compensation committee effective June 29, 2026, citing a transition into retirement. \* CEO Erik Lundgren was appointed to the board as a Class II director on July 5, 2026, with a term running to the 2028 annual meeting. \* Lundgren was not named to any board committee. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-26-000916), on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)

## Related News & Research

- [IMUX: Pivotal phase III data for vidofludimus calcium in relapsing MS expected by year-end, targeting NDA in 2025](https://longbridge.com/en/news/298495158.md)
- [IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026](https://longbridge.com/en/news/298485112.md)
- [Immunic director Duane Nash resigns, board shrinks to nine members](https://longbridge.com/en/news/298771566.md)
- [Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans](https://longbridge.com/en/news/298462931.md)
- [Immunic, Inc. $IMUX Shares Acquired by Bank of America Corp DE](https://longbridge.com/en/news/298823755.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**